TABLE 2.
Comparision of major adverse cardiac events between two groups
Atorvastatin (n=327) | Control (n=321) | P | |
---|---|---|---|
Myocardial infarction*, n (%) | 20 (6.4) | 39 (12.3) | 0.013 |
Revascularization, n (%) | 60 (19.2) | 84 (26.6) | 0.029 |
All-cause death, n (%) | 16 (5.1) | 25 (7.9) | 0.196 |
Combined end points, n (%) | 84 (26.9) | 131 (41.5) | <0.001 |
Including fatal and nonfatal myocardial infarction